1389 An assessment of ROR1 expression across tumor tissue and the investigation of a ROR1-targeted T cell engager as a therapeutic strategy to target ROR1 positive tumors

• Daniel Snell,
• Niels Kirk,
• David Urech,
• Nicole Bassler,
• Lucia Campos Carrascosa,
• Pawel Chrom,
• Peter Lichtlen

Affiliations

Daniel Snell

Numab Therapeutics AG, Horgen, Switzerland

Niels Kirk

Numab Therapeutics AG, Horgen, Switzerland

David Urech

Numab Therapeutics AG, Horgen, Switzerland

Nicole Bassler

Numab Therapeutics AG, Horgen, Switzerland

Lucia Campos Carrascosa

Numab Therapeutics AG, Horgen, Switzerland

Pawel Chrom

Numab Therapeutics AG, Horgen, Switzerland

Peter Lichtlen

Numab Therapeutics AG, Horgen, Switzerland